Table 1.
Distribution (median, maximum, and minimum) of polygenicity parameters across phenotypic categories in populations of East Asian and European descent (EAS and EUR, respectively)
| Category | EAS, median (max–min) | EUR, median (max–min) | ||||||
|---|---|---|---|---|---|---|---|---|
| N | πc | σ2 | a | N | πc | σ2 | a | |
| Body structures | 4 |
7.1e−3 (1e−2–4.7e−3) |
2e−5 (1e−4–1e−5) |
2e−6 (3e−6–1e−6) |
1 | 5e−3 | < 1e−6 | 2e−6 |
| Cardiovascular | 22 |
5e−3 (6.7e−3–6e−4) |
7.4e−5 (8e−4– < 1e−6) |
1e−6 (2e−5– − 2e−4) |
18 |
5e−3 (5e−3–1.7e−3) |
1e−4 (3e−4– < 1e−6) |
2e−6 (1e−5– − 2e−5) |
| Dermatological | 4 |
5e−3 (5.1e−3–5e−5) |
< 1e−6 (1.3e−2– < 1e−6) |
5e−6 (1.1e−1– − 1e−4) |
4 |
5e−3 (5e−3–4.4e−3) |
3e−4 (4e−4– < 1e−6) |
− 2e−5 (− 2e−6– − 2e−4) |
| Ear, nose, throat | 5 |
5e−3 (6.5e−3–5e−3) |
2e−4 (6e−4– < 1e−6) |
− 1e−5 (1e−5– − 1e−4) |
5 |
5e−3 (5e−3–4e−4) |
1e−4 (2.1e−3–1e−4) |
1e−6 (1e−5– − 1e−5) |
| Endocrine | 5 |
5e−3 (5e−3–1e−4) |
4e−5 (8.9e−3– < 1e−6) |
1e−5 (2e−5– − 3e−6) |
5 |
1e−4 (1.4e−3–5e−5) |
8.1e−3 (1.8e−2–4e−4) |
1e−5 (2e−5–4e−6) |
| Environment | 1 | 5e−3 | 1e−4 | − 2e−6 | 1 | 5e−3 | 5e−5 | 1e−6 |
| Gastrointestinal | 8 |
5e−3 (5e−3–1.1e−3) |
4e−5 (6e−4– < 1e−6) |
1e−6 (3e−5– − 2e−5) |
7 |
5e−3 (1.1e−2–1e−3) |
3e−5 (8e−4– < 1e−6) |
4e−6 (1e−5– − 3e−6) |
| Hematological | 18 |
1.5e−3 (5e−3–2e−4) |
1e−4 (3e−4– < 1e−6) |
1e−6 (1e−5– − 1.3e−3) |
4 |
5e−3 (5e−3–5e−3) |
4e−5 (1e−4– < 1e−6) |
1e−6 (3e−6– − 1e−4) |
| Immunological | 28 |
5e−3 (7.1e−3–2e−5) |
2e−4 (1e−2– < 1e−6) |
< 1e−6 (8e−5– − 2e−4) |
27 |
5e−3 (6.7e−3–3e−5) |
1e−4 (3.6e−2– < 1e−6) |
2e−6 (2e−5– − 6e−4) |
| Medication | 22 |
5e−3 (6.2e−3–1e−4) |
1e−4 (3.2e−3–1e−5) |
1e−6 (1e−5– − 3e−5) |
0 | NA | NA | NA |
| Metabolic | 31 |
1.8e−3 (5.2e−3–2e−5) |
1e−4 (7.9e−3– < 1e−6) |
1e−6 (1e−5– − 4e−5) |
15 |
5e−3 (0.78–3e−5) |
1e−4 (4.3e−2– < 1e−6) |
4e−6 (1e−4– − 2e−5) |
| Musculoskeletal | 9 |
5e−3 (5e−3–1e−4) |
< 1e−6 (5e−3– < 1e−6) |
1e−6 (5e−5– − 4e−4) |
9 |
5e−3 (1.1e−2–1.7e−3) |
5e−5 (4e−4– < 1e−6) |
2e−6 (1e−5– − 4e−4) |
| Neoplasms | 17 |
5e−3 (6e−3–3e−5) |
3e−4 (3.2e−2– < 1e−6) |
2e−6 (1e−4– − 1e−4) |
17 |
5e−3 (5e−3–2e−5) |
2e−4 (3e−2– < 1e−6) |
4e−6 (3e−5– − 3e−5) |
| Neurological | 7 |
5e−3 (5.2e−3–3.2e−3) |
1e−4 (1.8e−3– < 1e−6) |
− 1e−5 (4e−6– − 2e−4) |
6 |
5e−3 (5e−3–3.6e−3) |
1e−4 (2e−4– < 1e−6) |
− 4e−6 (1e−5– − 4e−5) |
| Ophthalmological | 8 |
5e−3 (5e−3–8e−4) |
5e−5 (4e−4– < 1e−6) |
< 1e−6 (2e−5– − 2e−5) |
7 |
2e−3 (5e−3–3e−5) |
3e−4 (2e−2– < 1e−6) |
5e−6 (1e−5– − 2e−6) |
| Psychiatric | 5 |
5e−3 (6.7e−3–5e−3) |
2e−4 (1.8e−3– < 1e−6) |
− 2e−5 (1e−5– − 2e−4) |
5 |
5e−3 (9e−3–5e−3) |
1e−4 (3e−4–1e−4) |
2e−6 (3e−6– − 1e−5) |
| Respiratory | 9 |
5e−3 (5e−3–5e−3) |
< 1e−6 (2e−4– < 1e−6) |
− 1e−5 (1e−5– − 1e−4) |
9 |
5e−3 (8.4e−3–2e−4) |
1e−4 (2.1e−3–2e−5) |
− 3e−6 (1e−5– − 1e−5) |
| Urogenital | 12 |
5e−3 (5.5e−3–3e−4) |
4e−6 (1.5e−3– < 1e−6) |
− 2e−6 (3e−5– − 1e−4) |
12 |
5e−3 (5e−3–1e−4) |
1e−4 (1.4e−3– < 1e−6) |
3e−6 (4e−6– − 2e−6) |
Estimates are reported using a scientific notation. Maximum and minimum estimates are not included for categories including a single trait
πc The proportion of susceptibility SNPs per trait, σ2 The variance parameter for non-null SNPs, a Residual effects not captured by the variance of effect sizes, NA not available